The NAD+ molecule and human research
The coenzyme, its building materials, and the difference between a blood result and a health outcome.
What the human trials measured
Human NAD+ research frequently involves a precursor: a substance cells can use to make NAD+. Two common examples are nicotinamide mononucleotide, or NMN, and nicotinamide riboside, or NR. They are different molecules from NAD+ itself. Keeping their names attached to findings prevents a result from being stretched to another preparation.
In a 2023 NMN trial in middle-aged adults, researchers measured higher blood NAD+ along with improvements in walking distance and quality-of-life scores. That is a result from a defined oral intervention and a defined study population. It does not establish an effect from an NAD+ infusion, nor does it prove that the intervention extends life.

NAD+ helps enzymes do their work
NAD+ stands for nicotinamide adenine dinucleotide. It is a dinucleotide, made of two linked nucleotide units, rather than a peptide chain. It acts as a coenzyme: a helper used by enzymes during chemical reactions. A 2021 review of NAD+ metabolism explains its roles in energy production and cellular signaling.
The oxidized form, NAD+, can accept electrons and become NADH. Reactions involving this pair connect the breakdown of nutrients with the processes that produce ATP, a molecule cells use to transfer energy. NAD+ also gets consumed by enzymes involved in signaling and repair. Cells therefore need ways to replenish it as well as use it.
How cells replenish NAD+
Cells can make NAD+ through several routes. One begins with tryptophan, an amino acid; another uses nicotinic acid. The salvage pathway recycles nicotinamide released when NAD+ is consumed. These routes are described in the metabolism review.
Within salvage, an enzyme called NAMPT helps convert nicotinamide into NMN, which can then become NAD+. NR enters through conversion to NMN. This chemistry provides a reason to study precursors, but a plausible pathway is only the beginning of a treatment question. Researchers still need to find out what changes in a particular tissue and whether that change matters for health.
A muscle result with clear limits
In a 2021 trial in prediabetic, postmenopausal women, oral NMN improved muscle insulin sensitivity over ten weeks. Insulin sensitivity describes how readily tissue responds to insulin, a hormone involved in blood sugar regulation. Neither body composition nor HbA1c changed; HbA1c reflects blood sugar over a longer period.
The unchanged outcomes belong beside the favorable result. Reporting only the muscle finding would make the trial sound broader than it was. The study does not establish a general weight-loss effect or show that all adults would respond similarly. Its population, duration, and choice of measurements give the result its meaning and its limits.
Blood NAD+ and longer-term health
A 2019 controlled trial of oral NR found increases in whole-blood NAD+ in healthy overweight adults. The participants' short-term tolerability findings were reassuring within that trial. Raising a blood measurement, however, does not by itself demonstrate better function in every tissue.
The 2025 assessment of human precursor trials describes limited human clinical efficacy and sparse information about tissue-specific NAD+ changes. Long-term disease prevention and longer life are larger questions than a blood increase can settle. The review also cautions against assuming that age-related patterns found in rodents have been established equally well across human tissues.
Why the heart experiment is different
A 2025 paper on cardiac ketone production combined work in human heart tissue with a mouse model of heart failure with preserved ejection fraction. In the mice, NAD+ repletion restored activity of HMGCS2, an enzyme involved in ketone production, and improved cardiac function. Disrupting that enzyme in heart muscle cells prevented the rescue.
Human tissue gives the mechanism relevance to human biology. The functional rescue still came from the animal model. The paper cannot establish that NAD+ treats heart failure in patients. It illustrates why a page can discuss a compelling experiment while keeping the resulting clinical question open.
Safety depends on the preparation
The oral NMN and NR trials do not answer the safety questions for injected or infused NAD+. The source literature describes infusion discomfort and contamination concerns with compounded preparations. FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality.
Short studies also cannot settle safety over years or in every medical condition. NAD+ participates in many processes, including those used by existing cancer cells; its role in cancer biology is complex rather than a simple benefit or harm claim. This page offers no universal daily regimen. The comparison and FAQ place these limits beside the much earlier MOTS-c evidence.